A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type. [electronic resource]
Producer: 20190613Description: 1982-1989 p. digitalISSN:- 1523-1747
- Aged
- Aged, 80 and over
- Biopsy
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Female
- France -- epidemiology
- Humans
- Immunologic Factors -- administration & dosage
- Leg
- Lenalidomide -- administration & dosage
- Lymphoma, Large B-Cell, Diffuse -- drug therapy
- Male
- Neoplasm Recurrence, Local
- Remission Induction
- Skin -- pathology
- Skin Neoplasms -- drug therapy
- Survival Rate -- trends
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.